Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

US7235576B1 · kind B1 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Bernd Riedl · Wuppertal, DE
• Jacques Dumas · Neuilly-Plaisance, FR
• Uday Khire · Hamden, US
• Timothy B. Lowinger · Carlisle, US
• William Scott · Guilford, US
• Roger Smith · Madison, US
• Jill Wood · Hampton, US
• Mary-Katherine Monahan · Hamden, US
• Reina Natero · Hamden, US
• Joel Renick · San Diego, US
• Robert Sibley · North Haven, US

Key dates

• Filing date: Jan 11, 2002
• Grant date: Jun 26, 2007
• Expiry date: Jan 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.